While systemic deletion of Akt isoforms validated Akt1 as a suitable target for cancer therapy in hormone receptor-positive and HER2-enriched breast cancers, it remains to be seen how systemic deletion of Akt1, Akt2 and Akt3 in different subtypes of breast cancer affects breast cancer development and progression. This evidence concerns the gene AKT3 and breast carcinoma.